NIH funds Celdara for pandemic influenza antiviral development

By The Science Advisory Board staff writers

August 12, 2020 -- The U.S. National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases has awarded Celdara Medical a Small Business Innovation Research (SBIR) grant for the development of antivirals against pandemic and interpandemic influenzas.

The funding will support proof-of-concept efforts through Celdara's Pandemic Security Initiative. The initiative is a framework for public-private partnerships that incorporates science, entrepreneurship, public-sector investment, and private-sector business acumen to develop and produce treatments and vaccines that will address future pandemic threats.

Celdara's Academic Partner Network includes collaborations with 60 leading universities, and thousands of pipeline innovations from all 50 states.

NIH awards Boragen grant for antimalarial drug discovery
Boron-based discovery platform firm Boragen has received a phase I Small Business Innovation Research grant from the U.S. National Institutes of Health...
Dragonfly, Bristol Myers Squibb to develop immunotherapies
Dragonfly Therapeutics has entered into a research collaboration with Bristol Myers Squibb to discover and develop novel immunotherapies for multiple...
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...

Copyright © 2020

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter